TP53 and brain neoplasm: By adapting the method developed by Alexandrov and colleagues to assign specific signatures to mutational processes in human tumors20, we identified mutational signatures contributing to somatic mutations in brain tumors developing in BRCA2/p53, Lig4/p53, and XRCC4/p53-deficient mice (Fig. 4d).